Benedikt Mortzfeld to Anti-Bacterial Agents
This is a "connection" page, showing publications Benedikt Mortzfeld has written about Anti-Bacterial Agents.
Connection Strength
1.396
-
Bhattarai SK, Bucci V, Mortzfeld BM. Ec W: A Novel Narrow-Spectrum Class IIb Microcin from Escherichia coli. Probiotics Antimicrob Proteins. 2026 01; 18(1):560-566.
Score: 0.579
-
Mortzfeld BM, Bhattarai SK, Bucci V. Novel class IIb microcins show activity against Gram-negative ESKAPE and plant pathogens. Elife. 2024 Dec 11; 13.
Score: 0.565
-
Mortzfeld BM, Palmer JD, Bhattarai SK, Dupre HL, Mercado-Lubio R, Silby MW, Bang C, McCormick BA, Bucci V. Microcin MccI47 selectively inhibits enteric bacteria and reduces carbapenem-resistant Klebsiella pneumoniae colonization in vivo when administered via an engineered live biotherapeutic. Gut Microbes. 2022 Jan-Dec; 14(1):2127633.
Score: 0.115
-
Palmer JD, Mortzfeld BM, Piattelli E, Silby MW, McCormick BA, Bucci V. Microcin H47: A Class IIb Microcin with Potent Activity Against Multidrug Resistant Enterobacteriaceae. ACS Infect Dis. 2020 04 10; 6(4):672-679.
Score: 0.101
-
Kellogg TD, Ceglia S, Mortzfeld BM, Tanna TM, Zeamer AL, Mancini MR, Foley SE, Ward DV, Bhattarai SK, McCormick BA, Reboldi A, Bucci V. Succinate-producing microbiota drives tuft cell hyperplasia to protect against Clostridioides difficile. J Exp Med. 2025 Jan 06; 222(1).
Score: 0.035